Product Overview
Blocking/Immunizing peptide for anti-PHEMX/TSPAN32 antibody
Tag/Conjugate
Unconjugated
Application Notes
For in vitro research use only. Not intended for any diagnostic or therapeutic purpose. Not for human or animal consumption.
Format
Lyophilized powder
Storage
Shipped at ambient temperature, store at -20°C.
Antigen Description
This gene, which is a member of the tetraspanin superfamily, is one of several tumor-suppressing subtransferable fragments located in the imprinted gene domain of chromosome 11p15.5, an important tumor-suppressor gene region. Alterations in this region have been associated with Beckwith-Wiedemann syndrome, Wilms tumor, rhabdomyosarcoma, adrenocortical carcinoma, and lung, ovarian and breast cancers. This gene is located among several imprinted genes; however, this gene, as well as the tumor-suppressing subchromosomal transferable fragment 4, escapes imprinting. This gene may play a role in malignancies and diseases that involve this region, and it is also involved in hematopoietic cell function. Alternatively spliced transcript variants have been described, but their biological validity has not been determined. [provided by RefSeq, Jul 2008]
Function
molecular_function;
Synonyms
TSPAN32; tetraspanin 32; ART1; PHMX; PHEMX; TSSC6; tetraspanin-32; tspan-32; protein Phemx; tumor-suppressing STF cDNA 6; pan-hematopoietic expression protein; tumor-suppressing subtransferable candidate 6; tumor-suppressing subchromosomal transferable fragment cDNA 6;
Citations
Have you cited CDBP2283 in a publication?
Let us know and earn a reward for your research.
| Product Name |
Cat. No. |
Applications |
Host Species |
Datasheet |
Price |
Add to Basket |
| Product Name |
Cat. No. |
Applications |
Host Species |
Datasheet |
Price |
Add to Basket |
Geary, SM; Cambareri, AC; et al. Differential tissue expression of epitopes of the tetraspanin CD151 recognised by monoclonal antibodies. TISSUE ANTIGENS 58:141-153(2001).
Gopal, AK; Tarantolo, SR; et al. Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR (TM) therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. INVESTIGATIONAL NEW DRUGS 32:1213-1225(2014).